Journal article
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Abstract
BACKGROUND: Amplification or deletion of the topoisomerase II alpha (TOP2A) gene in breast cancers has been postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy than amplification of the human epidermal growth factor receptor type 2 (HER2) gene.
METHODS: We studied 438 tumors from 710 premenopausal women with node-positive breast cancer who received cyclophosphamide, epirubicin, and …
Authors
O’Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
Journal
Journal of the National Cancer Institute, Vol. 101, No. 9, pp. 644–650
Publisher
Oxford University Press (OUP)
Publication Date
May 6, 2009
DOI
10.1093/jnci/djp067
ISSN
0027-8874
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAnthracyclinesAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDNA Topoisomerases, Type IIDNA-Binding ProteinsDisease-Free SurvivalFemaleGene AmplificationGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGenes, erbB-2HumansKaplan-Meier EstimateLymphatic MetastasisMastectomyMiddle AgedOligonucleotide Array Sequence AnalysisPoly-ADP-Ribose Binding ProteinsPremenopause